Compugen (NASDAQ:CGEN) Downgraded by Wall Street Zen to Sell

Compugen (NASDAQ:CGEN) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Compugen Price Performance

Shares of CGEN stock opened at $1.50 on Friday. Compugen has a 1 year low of $1.13 and a 1 year high of $2.66. The firm has a fifty day moving average price of $1.62 and a 200-day moving average price of $1.67. The company has a market cap of $133.86 million, a price-to-earnings ratio of -6.82 and a beta of 2.61.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Compugen had a negative net margin of 87.45% and a negative return on equity of 34.77%. The business had revenue of $1.26 million for the quarter, compared to the consensus estimate of $3.95 million. Equities research analysts expect that Compugen will post -0.03 EPS for the current year.

Institutional Investors Weigh In On Compugen

Hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. bought a new stake in Compugen during the fourth quarter valued at about $103,000. Commonwealth Equity Services LLC purchased a new position in shares of Compugen in the fourth quarter valued at about $32,000. Marshall Wace LLP lifted its position in shares of Compugen by 84.9% in the fourth quarter. Marshall Wace LLP now owns 88,169 shares of the biotechnology company’s stock valued at $135,000 after acquiring an additional 40,494 shares in the last quarter. Silverarc Capital Management LLC lifted its position in shares of Compugen by 8.2% in the fourth quarter. Silverarc Capital Management LLC now owns 1,624,377 shares of the biotechnology company’s stock valued at $2,485,000 after acquiring an additional 123,264 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of Compugen by 936.9% in the fourth quarter. Northern Trust Corp now owns 941,825 shares of the biotechnology company’s stock valued at $1,441,000 after acquiring an additional 850,997 shares in the last quarter. Institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.